This website uses cookies to ensure that we give you the best experience on our website. Click here for more information.

ok

Terms of Use

The information contained in this site is for healthcare professionals only.

I am not a healthcare professional I confirm to be a healthcare professional
the prolia® patient

Prolia® (denosumab) for patients living with osteoporosis

People living with osteoporosis have an increased risk of fractures, particularly fractures of the spine, vertebrae, wrist, and femur. These fractures result in significant clinical and financial consequences for individuals and society. Treatment of osteoporosis patients aims to reduce the fracture risk that occur due to bone thinning and fragile bones, and Prolia® (denosumab) is a medication for osteoporosis that has been shown to reduce the risk of fractures of the spine as well as other fractures in postmenopausal women at increased risk of fracture.

Prolia® (denosumab) therapy and patient characteristics

The following patient characteristics and their relationship with Prolia® (denosumab) have been assessed:

  • Ethnicity: Data are limited in terms of ethnicity, however no notable differences have been observed between Caucasians and non-Caucasians on Prolia® (denosumab) therapy.
  • Age: While exposure has been observed to be lower in older (65-80 years) compared to younger (less than 65 years) postmenopausal osteoporosis patients, no differences in pharmacodynamics have been observed. No dose adjustment is required in elderly patients. Prolia® (denosumab) has not been studied in children.
  • Weight: While exposure has been observed to be lower for patients of heigher body weight, body weight does not influence the pharmacodynamic effect of Prolia® (denosumab). 


Osteoporosis in women

Osteoporosis may occur in women after menopause. In post menopausal women with osteoporosis Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures. 

learn more

Osteoporosis in men

Osteoporosis in men may be due to aging, low level of the male hormone, testosterone or hormone ablation therapy. In men with prostate cancer receiving hormone ablation, Prolia® (denosumab) significantly reduces the risk of vertebral fractures. 

learn more